全文获取类型
收费全文 | 3885篇 |
免费 | 268篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 144篇 |
妇产科学 | 82篇 |
基础医学 | 530篇 |
口腔科学 | 106篇 |
临床医学 | 390篇 |
内科学 | 824篇 |
皮肤病学 | 65篇 |
神经病学 | 507篇 |
特种医学 | 117篇 |
外科学 | 392篇 |
综合类 | 10篇 |
预防医学 | 294篇 |
眼科学 | 99篇 |
药学 | 240篇 |
中国医学 | 2篇 |
肿瘤学 | 335篇 |
出版年
2023年 | 37篇 |
2022年 | 69篇 |
2021年 | 127篇 |
2020年 | 83篇 |
2019年 | 105篇 |
2018年 | 121篇 |
2017年 | 127篇 |
2016年 | 130篇 |
2015年 | 122篇 |
2014年 | 155篇 |
2013年 | 199篇 |
2012年 | 303篇 |
2011年 | 280篇 |
2010年 | 155篇 |
2009年 | 133篇 |
2008年 | 245篇 |
2007年 | 267篇 |
2006年 | 235篇 |
2005年 | 273篇 |
2004年 | 222篇 |
2003年 | 183篇 |
2002年 | 184篇 |
2001年 | 36篇 |
2000年 | 30篇 |
1999年 | 31篇 |
1998年 | 35篇 |
1997年 | 30篇 |
1996年 | 22篇 |
1995年 | 24篇 |
1994年 | 18篇 |
1993年 | 10篇 |
1992年 | 12篇 |
1991年 | 6篇 |
1990年 | 5篇 |
1989年 | 10篇 |
1988年 | 13篇 |
1987年 | 6篇 |
1986年 | 7篇 |
1985年 | 8篇 |
1984年 | 7篇 |
1983年 | 12篇 |
1982年 | 5篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1972年 | 11篇 |
1971年 | 5篇 |
1970年 | 6篇 |
1969年 | 4篇 |
1961年 | 4篇 |
1956年 | 4篇 |
排序方式: 共有4172条查询结果,搜索用时 15 毫秒
81.
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant 总被引:8,自引:0,他引:8
Barkan AL Burman P Clemmons DR Drake WM Gagel RF Harris PE Trainer PJ van der Lely AJ Vance ML 《The Journal of clinical endocrinology and metabolism》2005,90(10):5684-5691
CONTEXT: In clinical practice, patients with acromegaly may be switched from therapy with long-acting somatostatin analogs to pegvisomant. The effect of changing therapies on glucose homeostasis and safety has not been reported. OBJECTIVES: The objectives of this study were to monitor changes in IGF-I levels, glycemic control, and safety, particularly liver function and tumor size. DESIGN: This was a multicenter, open-label, 32-wk trial study. SETTING: The study was performed at outpatient clinics. PATIENTS: Fifty-three patients with acromegaly previously treated with octreotide long-acting release (LAR) participated in this study. Intervention: Pegvisomant (10 mg/d) was initiated 4 wk after the last dose of octreotide LAR and was adjusted based on serum IGF-I concentrations at wk 12, 20, and 28. MAIN OUTCOME MEASURES: The main outcome measures were changes in IGF-I, glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose, and safety during the first 12 wk after conversion. RESULTS: At the end of pegvisomant treatment, IGF-I was normalized in 78% of patients. At wk 32, median fasting glucose concentration and HbA1c were reduced (-1.4 mmol/liter and -0.4%, respectively; both P < or = 0.0001) in the study population. Improvements in glycemic control occurred in patients with normal IGF-I concentrations at wk 4 [n = 15; fasting glucose, -1.7 mmol/liter (P < or = 0.0001); HbA1c -0.2% (P = 0.03)]. Decreases in fasting glucose and HbA1c levels were observed in patients with and without diabetes. HbA1c was reduced by more than 1.0% in patients with diabetes. Median pituitary tumor volume did not change, although tumor volume increased in two patients with macroadenomas. CONCLUSIONS: Conversion from octreotide LAR to pegvisomant was safe and well tolerated. Improved glycemic control indicates that pegvisomant should be considered in patients with acromegaly and diabetes. 相似文献
82.
83.
Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County,Denmark 总被引:9,自引:0,他引:9
BACKGROUND & AIMS: A population-based cohort comprising 374 patients with Crohn's disease diagnosed in Copenhagen County between 1962 and 1987 was observed until 1997 for mortality and causes of death. METHODS: Observed deaths were compared with expected deaths calculated by using individually computed person-years at risk and 1995 rates for Copenhagen County. Cumulative survival curves were calculated. RESULTS: A total of 84 deaths occurred vs. 67 expected (standardized mortality ratio [SMR], 1.3; 95% confidence interval [CI], 1.01-1.56): 45 women vs. 31.8 expected (SMR, 1.4; 95% CI, 1.03-1.89) and 39 men vs. 35.2 expected (SMR, 1.1; 95% CI, 0.79-1.51). An excess mortality was observed among women observed for 21-25 years after diagnosis. Among women aged <50 years at diagnosis, 25 deaths were observed vs. 7.3 expected (SMR, 3.42; 95% CI, 2.21-5.04). Fourteen (31%) of the observed deaths among women and 8 (21%) among men had a certain or possible connection to Crohn's disease. Among causes of death unrelated to Crohn's disease, an overrepresentation of gastrointestinal diseases, infections, and diseases of the urinary organs was observed. CONCLUSIONS: An increased mortality was observed late in the disease course that was most pronounced among women younger than 50 years at diagnosis and was attributed to death associated with severe Crohn's disease. 相似文献
84.
85.
86.
Livneh Nir Braeken Dionne Drozdinsky Genady Gafter-Gvili Anat Seelig Jaap Rozovski Uri Berger Tamar Raanani Pia Falanga Anna ten Cate Hugo Spectre Galia Leader Avi 《Journal of thrombosis and thrombolysis》2021,52(2):590-596
Journal of Thrombosis and Thrombolysis - Managing anticoagulation in hematological malignancy patients with atrial fibrillation and thrombocytopenia is a clinical challenge with limited data. We... 相似文献
87.
88.
89.
Isolated left ventricular noncompaction 总被引:2,自引:0,他引:2
Carerj S Calabrò MP Cerrito M Lembo D Parisi R Raffa S 《Echocardiography (Mount Kisco, N.Y.)》2004,21(5):437-438
90.
Pre-Menopausal Breast Fat Density Might Predict MACE During 10 Years of Follow-Up: The BRECARD Study
Celestino Sardu Gianluca Gatta Gorizio Pieretti Luigi Viola Cosimo Sacra Graziella Di Grezia Lanfranco Musto Salvatore Minelli Daniele La Forgia Mariangela Capodieci Alessandro Galiano Angela Vestito Angela De Lisio Pia Clara Pafundi Ferdinando Carlo Sasso Salvatore Cappabianca Gianfranco Nicoletti Giuseppe Paolisso Raffaele Marfella 《JACC: Cardiovascular Imaging》2021,14(2):426-438
ObjectivesThis study sought to determine whether the breast gland adipose tissue is associated with different rates of major adverse cardiac events (MACEs) in pre-menopausal women.BackgroundTo our knowledge, no study investigated the impact of breast adipose tissue infiltration on MACEs in pre-menopausal women.MethodsProspective multicenter cohort study conducted on pre-menopausal women >40 years of age without cardiovascular disease and breast cancer at enrollment. The study started in January 2000 and ended in January 2009, and the end of the follow-up for the evaluation of MACEs was in January 2019. Participants underwent mammography to evaluate breast density and were divided into 4 groups according to their breast density. The primary endpoint was the probability of a MACE at 10 years of follow-up in patients staged for different breast deposition/adipose tissue deposition.ResultsThe propensity score matching divided the baseline population of 16,763 pre-menopausal women, leaving 3,272 women according to the category of breast density from A to D. These women were assigned to 4 groups of the study according to baseline breast density. At 10 years of follow-up, we had 160 MACEs in group 1, 62 MACEs in group 2, 27 MACEs in group 3, and 16 MACEs in group 4. MACEs were predicted by the initial diagnosis of lowest breast density (hazard ratio: 3.483; 95% confidence interval: 1.476 to 8.257). Further randomized clinical trials are needed to translate the results of the present study into clinical practice. The loss of ex vivo breast density models to study the cellular/molecular pathways implied in MACE is another study limitation.ConclusionsAmong pre-menopausal women, a higher evidence of adipose tissue at the level of breast gland (lowest breast density, category A) versus higher breast density shows higher rates of MACEs. Therefore, the screening mammography could be proposed in overweight women to stage breast density and to predict MACEs. (Breast Density in Pre-menopausal Women Is Predictive of Cardiovascular Outcomes at 10 Years of Follow-Up [BRECARD]; NCT03779217) 相似文献